Petrus Trust Company’s Cardlytics CDLX Stock Holding History

Petrus Trust Company’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-312	Closed	-$206K	–	84
2021 Q4	$206K	Buy	+312	New	+$239K	0.02%	104

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

ACM

Alua Capital Management New York $1.13B AUM 8.41% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $620M AUM 14.15% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

JCM

JS Capital Management New York $109M AUM 34.13% 1-Year Est. Return

Petrus Trust Company's CDLX Position: Q1 2022 in Review

Petrus Trust Company sold out of Cardlytics (CDLX) in Q1 2022, closing a stake of 312 shares — an estimated $206K sold.

Petrus Trust Company first reported a position in CDLX in Q4 2021 and held it in 1 quarter. The position peaked at $206K in Q4 2021. 153 funds tracked by Wall St. Rank hold CDLX as of Q1 2022.

Petrus Trust Company reported no remaining Cardlytics position as of Q1 2022 after selling out during the quarter.
Petrus Trust Company sold 312 Cardlytics shares in Q1 2022, an estimated $206K.
Petrus Trust Company first reported a position in Cardlytics in Q4 2021 and held it in 1 quarter.
Petrus Trust Company's Cardlytics position peaked at $206K in Q4 2021.
153 funds tracked by Wall St. Rank held Cardlytics as of Q1 2022.

Based on Petrus Trust Company's 13F filing for Q1 2022, filed 16 May 2022.